Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Drug pricing stories

Nov 12, 2026

FDA quietly shelves Trump's drug fast-track voucher program amid agency chaos

No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.

Nov 12, 2026·2 sources
00
Nov 9, 2026

FDA approves Bayer's asundexian as first-in-class factor XIa inhibitor for stroke prevention

The FDA approved asundexian (Sunharbo), a novel blood thinner from Bayer, to reduce the risk of recurrent stroke in adults, marking the first approval in the factor XIa inhibitor class.

Nov 9, 2026·6 sources
00
Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Nov 2, 2026

FDA approves generic version of HIV-prevention shot lenacapavir

The U.S. Food and Drug Administration has approved a generic version of the world's only twice-a-year shot to prevent HIV, a significant step toward making the drug available inexpensively and more quickly in low-income countries.

Nov 2, 2026·2 sources
00
Oct 28, 2026

Labor Department finalizes rule requiring PBMs to disclose fees and compensation

The Trump administration finalized a sweeping regulation requiring pharmacy benefit managers to share detailed fee and compensation data with self-funded employer clients starting in 2027. Employers praised the transparency measure while PBMs criticized it as burdensome.

Oct 28, 2026·3 sources
00
Oct 15, 2026

Trump administration delays rule restricting imported medicines from Canada

The U.S. government has delayed by 90 days the implementation of new customs requirements for small international mail shipments, postponing potential restrictions on Americans' access to cheaper prescription drugs imported from Canada and other countries. The delay pushes implementation past the November midterm elections.

Oct 15, 2026·3 sources
00
Oct 13, 2026

FTC asks court to hold Martin Shkreli in contempt for violating lifetime pharma ban

Federal Trade Commission and seven states asked a federal judge to hold Martin Shkreli in contempt, alleging he has traded pharmaceutical stocks on YouTube for years in violation of a lifetime ban from the drug industry.

Oct 13, 2026·6 sources
00
Sep 28, 2026

Medicare drug price negotiations strain oncology practices despite patient cost relief

The Inflation Reduction Act's Medicare out-of-pocket cap is reducing costs for cancer patients, but community oncology leaders warn that negotiated drug price cuts are creating financial pressures on medical practices.

Sep 28, 2026·2 sources
00
Sep 25, 2026

340B drug program faces renewed scrutiny over hospital charity care spending and reform proposals

The 340B drug discount program is under debate as a new report shows participating hospitals lag behind peers in charity care spending, while stakeholders at a conference discuss potential reforms including data clearinghouses and a 2027 rebate model. Critics argue the program has expanded without corresponding patient benefits.

Sep 25, 2026·2 sources
00
Sep 20, 2026

Novo Nordisk cuts 13,000 jobs as CEO outlines strategy beyond weight-loss drugs

Novo Nordisk announced it cut 13,000 jobs in the past year and outlined plans to diversify beyond obesity drugs with new pipeline assets and bolt-on acquisitions. CEO Mike Doustdar faced investor skepticism about pricing power and strategy ahead of patent expiries.

Sep 20, 2026·9 sources
00
Sep 14, 2026

US, India launch initiatives to accelerate drug approval processes

The FDA is accepting applications for a pilot program to expedite drug testing in humans, while at least 19 US states have applied for a Medicaid drug-pricing experiment with international benchmarking. Separately, India's government is streamlining its drug approval process by allowing studies to begin after notifying regulators and cutting import license processing times in half.

Sep 14, 2026·3 sources
00

Scholar Rock's spinal muscular atrophy drug Isembyld approved by FDA

The FDA approved Isembyld (apitegromab), the first muscle-targeted treatment for spinal muscular atrophy. The drug will cost approximately $310,000 annually and showed improvements in motor function in clinical trials.

Sep 14, 2026·3 sources
00
Sep 3, 2026

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

The FDA approved Zanvastro, an antisense oligonucleotide therapy from Ionis Pharmaceuticals, as the first targeted treatment for Alexander disease, a rare and deadly genetic neurological disorder affecting adults and children. The company priced the injectable drug at $285,000 per dose.

Sep 3, 2026·5 sources
00
Aug 14, 2026

Two-thirds of new drugs launched above cost-effectiveness thresholds, ICER reports

A new ICER analysis found that net launch prices for new medicines spiked significantly between 2022 and 2025, with two-thirds of new drugs priced above cost-effectiveness guidelines. About a quarter of drugs launched in the most recent year had annual net prices exceeding $500,000.

Aug 14, 2026·5 sources
00
Jul 7, 2026

CMS Proposes Cuts to 340B Drug Pricing Program Payments in 2027 Medicare Rule

The Centers for Medicare & Medicaid Services has proposed cutting Medicare payments for drugs purchased under the 340B Drug Pricing Program in its 2027 rule, reigniting a long-standing dispute between safety-net hospitals and federal regulators over the program designed to help vulnerable populations access medications.

Jul 7, 2026·2 sources
00
Jul 2, 2026

Trump Administration Proposes Rule to Block Hospital Markups on Discounted Medicare Drugs, Projecting $1.1 Billion in Savings

The Trump administration has proposed a new regulation through the Centers for Medicare & Medicaid Services targeting hospitals in the 340B Drug Pricing Program, aiming to prevent markups on discounted drugs for Medicare patients and potentially save consumers $1.1 billion next year.

Jul 2, 2026·4 sources
00
May 21, 2026

American Hospital Association sues HHS over 340B rebate pilot program

The American Hospital Association, along with a Maine hospital lobby and four safety-net hospitals, filed a lawsuit against HHS over the agency's plan to convert 340B drug discounts into a rebate system. This is the second time hospitals have sued to block such a program, alleging rebates will threaten their financial viability.

May 21, 2026·2 sources
00
May 18, 2026

Supreme Court Rejects Challenge to Medicare Drug Price Negotiation

The U.S. Supreme Court has rejected a legal challenge to Medicare's drug price negotiation program, a decision that may make remaining pharmaceutical industry lawsuits more difficult to pursue.

May 18, 2026·1 source
00
Apr 20, 2026

CVS Caremark Settles with FTC Over Drug Rebate Practices, Agrees to Count TrumpRx Purchases Toward Deductibles

CVS Health's Caremark pharmacy benefits unit reached a settlement with the U.S. Federal Trade Commission to curb controversial rebate practices in the pharmacy benefits market. The agreement requires Caremark to count consumer purchases from Trump's TrumpRx program toward insurance deductibles, mirroring a similar settlement previously reached with Cigna.

Apr 20, 2026·4 sources
00
Mar 13, 2026

Harvard Study Finds IRA Drug Reforms Helping Medicare Patients Stay on Medications

A Harvard-backed study found that the Inflation Reduction Act's drug provisions are helping Medicare beneficiaries stay on their medications. However, the reforms have not yet reduced overall healthcare costs or financial anxiety for beneficiaries.

Mar 13, 2026·2 sources
00
Dec 18, 2025

Trump announces all 50 states to participate in Medicaid 'most favored nation' drug pricing program

President Trump announced that all 50 states, Washington D.C., and Puerto Rico have agreed to participate in his administration's 'most favored nation' drug pricing initiative for Medicaid programs, which aims to lower prescription drug costs by tying prices to those paid in other countries.

Dec 18, 2025·6 sources
00

Top claims

  • ▪Germany's Merck KGaA's fertility treatment Pergoveris remained unapproved three months after the FDA accepted its final application following an eight-month rolling review, as of November 2026
  • ▪Former FDA Commissioner Marty Makary left the FDA in May 2026
  • ▪No new drugs have received a Commissioner's National Priority Voucher since former FDA Commissioner Marty Makary left the FDA in May 2026

People involved

Vinay PrasadDonald TrumpMartin Shkreli

Subtopics

Drug Policy, Pricing & Approval16Healthcare Policy10Healthcare Access and Insurance7Medication Pricing & Affordability6Drug Approval and Clinical Trials5FDA drug approval5Government and Regulatory Policy5Drug pricing policy4Medicare4Medicare & drug pricing policy4Clinical trials3FDA regulation & drug policy3Novo Nordisk3Pharma3Pharmaceutical Industry3Regulatory compliance3Trump administration3Accelerated approval pathways2Eli Lilly2FDA drug approval process2Federal agencies2Healthcare costs2International trade2New drug application (NDA) process2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories